IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA

/PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody...

Related Keywords

Tongji , Sichuan , China , Shanghai , Nanjing , Jiangsu , Huazhong , Hubei , Chinese , Lugui Qiu , Adimab Incyte , Chunrui Li , Eli Lilly , A Equecabtagene Autoleucel , Equecabtagene Autoleucel , Innovent Biologics , Innovent Biologics Inc , International Myeloma Society , Huazhong University Of Science Technology , Chinese Academy Of Medical Science Hematology Hospital , Md Anderson Cancer Center , Tongji Medical College , China National Medical Products Administration , Complete Response , Abstract Code , Myeloma Society , Annual Meeting , Refractory Multiple , Chinese Academy , Medical Science Hematology Hospital , Tongji Hospital , Huazhong University , New Drug Application , National Medical Products Administration , Sintilimab Injection , Bevacizumab Injection , Adalimumab Injection , Rituximab Injection , Pemigatinib Oral Inhibitor , Ramucirumab Injection , Selpercatinib Capsules , Equecabtagene Autoleucel Injection , Tafolecimab Injection , Cancer Center , Iaso Bio ,